Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder

Monoaminergic neurotransmitter (serotonin, norepinephrine and dopamine) mechanisms of disease dominated the research landscape in the pathophysiology and treatment of major depressive disorder (MDD) for more than 50 years and still dominate available treatment options. However, the sum of all brain...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Neural Transmission 2014-08, Vol.121 (8), p.907-924
Hauptverfasser:	Niciu, Mark J., Ionescu, Dawn F., Richards, Erica M., Zarate, Carlos A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Biomarkers, Pharmacological - metabolism Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Depressive Disorder, Major - immunology Depressive Disorder, Major - physiopathology Excitatory Amino Acid Agents - pharmacology Excitatory Amino Acid Agents - therapeutic use Glutamic Acid - metabolism Humans Ketamine - pharmacology Ketamine - therapeutic use Medicine Medicine & Public Health Neurology Neurosciences Psychiatry Psychiatry and Preclinical Psychiatric Studies - Review article Receptors, Glutamate - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Monoaminergic neurotransmitter (serotonin, norepinephrine and dopamine) mechanisms of disease dominated the research landscape in the pathophysiology and treatment of major depressive disorder (MDD) for more than 50 years and still dominate available treatment options. However, the sum of all brain neurons that use monoamines as their primary neurotransmitter is
ISSN:	0300-9564 1435-1463
DOI:	10.1007/s00702-013-1130-x